Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.55 |
| ▸ | LMNA | P02545 | 1/20 | 0.55 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.55 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.55 |
| ▸ | RXRA | P19793 | 14/20 | 0.38 |
| ▸ | RXRG | P48443 | 11/20 | 0.37 |
| ▸ | RXRB | P28702 | 8/20 | 0.37 |
| ▸ | RARA | P10276 | 2/20 | 0.36 |
| ▸ | RARB | P10826 | 2/20 | 0.36 |
| ▸ | RARG | P13631 | 2/20 | 0.36 |
| ▸ | KDM1A | O60341 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11769611 | 1.00 | ALDH1A1 (0.55) | ALDH1A1LMNACYP3A4TDP1RXRA | |
| SCHEMBL11860303 | 0.90 | CYP3A4 (0.54) | ALDH1A1LMNACYP3A4TDP1RXRA | |
| SCHEMBL11860309 | 0.90 | CYP3A4 (0.54) | ALDH1A1LMNACYP3A4TDP1RXRA | |
| SCHEMBL11811841 | 0.87 | ALDH1A1 (0.52) | ALDH1A1LMNACYP3A4TDP1RXRA | |
| SCHEMBL11811846 | 0.87 | ALDH1A1 (0.52) | ALDH1A1LMNACYP3A4TDP1RXRA | |
| SCHEMBL11758083 | 0.87 | CYP3A4 (0.54) | ALDH1A1LMNACYP3A4TDP1MEN1 | |
| SCHEMBL11758093 | 0.87 | CYP3A4 (0.54) | ALDH1A1LMNACYP3A4TDP1MEN1 | |
| SCHEMBL6448320 | 0.86 | ALDH1A1 (0.75) | ALDH1A1LMNACYP3A4TDP1RXRA | |
| SCHEMBL3052148 | 0.86 | ALDH1A1 (0.75) | ALDH1A1LMNACYP3A4TDP1RXRA | |
| SCHEMBL11500290 | 0.86 | ALDH1A1 (0.75) | ALDH1A1LMNACYP3A4TDP1RXRA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-4021461-A | INSECTICIDES | ZOECON CORPORATION (US) | 1977-05-03 | — | — | US | claimed |
| US-10980835-B2 | Arsenic trioxide for treatment of PIN1-associated disorders | BETH ISRAEL DEACONESS MEDICAL CENTER, INC. (US) | 2021-04-20 | — | — | US | disclosed |
| US-10548864-B2 | Enhanced ATRA-related compounds for the treatment of proliferative diseases, autoimmune diseases, and addiction conditions | BETH ISRAEL DEACONESS MEDICAL CENTER, INC. (US) | 2020-02-04 | — | — | US | disclosed |
| US-10265288-B2 | Methods and compositions for the treatment of proliferative disorders | BETH ISRAEL DEACONESS MEDICAL CENTER, INC. (US) | 2019-04-23 | — | — | US | disclosed |
| US-20180153934-A1 | ARSENIC TRIOXIDE FOR TREATMENT OF PIN1-ASSOCIATED DISORDERS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2018-06-07 | — | — | US | disclosed |
| US-20180064666-A1 | ENHANCED ATRA-RELATED COMPOUNDS FOR THE TREATMENT OF PROLIFERATIVE DISEASES, AUTOIMMUNE DISEASES, AND ADDICTION CONDITIONS | BETH ISRAEL DEACONESS MEDICAL CENTER, INC. | 2018-03-08 | — | — | US | disclosed |
| US-20170112792-A1 | ENHANCED ATRA-RELATED COMPOUNDS DERIVED FROM STRUCTURE-ACTIVITY RELATIONSHIPS AND MODELING FOR INHIBITING PIN1 | BETH ISRAEL DEACONESS MEDICAL CENTER, INC. | 2017-04-27 | — | — | US | disclosed |
| US-20150044278-A1 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF PROLIFERATIVE DISORDERS | BETH ISRAEL DEACONESS MEDICAL CENTER, INC. | 2015-02-12 | — | — | US | disclosed |
| US-20140086909-A1 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF PROLIFERATIVE DISORDERS | BETH ISRAEL DEACONESS MEDICAL CENTER, INC. (US) | 2014-03-27 | — | — | US | disclosed |
| US-3981922-A | INSECTICIDES | ZOECON CORPORATION (US) | 1976-09-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10980835-B2 | Arsenic trioxide for treatment of PIN1-associated disorders | PIN1, AS3MT, PML | ALDH1A1 2657/4885LMNA 3610/4885CYP3A4 4452/4885 |
| US-20180153934-A1 | ARSENIC TRIOXIDE FOR TREATMENT OF PIN1-ASSOCIATED DISORDERS | PIN1, AS3MT, PML | ALDH1A1 2657/4885LMNA 3610/4885CYP3A4 4452/4885 |
| US-10548864-B2 | Enhanced ATRA-related compounds for the treatment of proliferative diseases, autoimmune diseases, and addiction conditions | PIN1, RARB, RARA | ALDH1A1 1735/4885LMNA 4018/4885CYP3A4 3907/4885 |
| US-20180064666-A1 | ENHANCED ATRA-RELATED COMPOUNDS FOR THE TREATMENT OF PROLIFERATIVE DISEASES, AUTOIMMUNE DISEASES, AND ADDICTION CONDITIONS | PIN1, RARB, RARA | ALDH1A1 1735/4885LMNA 4018/4885CYP3A4 3907/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.